In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eleanor Malone

London, UK
Eleanor has been editor of Scrip Intelligence since 2014. She has more than 15 years’ experience writing specialist news and analysis for and about the biopharma industry. She holds an MA in modern languages from the University of Edinburgh. Based in London, she appears regularly on TV and radio and conference panels to discuss matters related to the industry.
Advertisement
Set Alert for Articles By Eleanor Malone

Latest From Eleanor Malone

What GSK's Immunology Chief Did Next

Paul Peter Tak recently defected from big pharma to East Coast venture firm Flagship Pioneering. He described the appeal of entrepreneurship in the biotech world and the value of taking the road less traveled when it comes to biomedical R&D.

Leadership Research and Development Strategies

Biogen To Launch Phase III Alzheimer’s Prevention Study

The firm announced plans to begin a Phase III study of aducanumab to prevent or delay the onset of Alzheimer’s, but refused to discuss ongoing studies during its fourth quarter earnings call.

Neurology Sales & Earnings

Q4 Earnings Preview: Pfizer, Amgen, Allergan, Biogen And Novartis

Pfizer's fourth-quarter call will be the first with new CEO Albert Bourla, while Amgen will provide reassurances after US Neulasta and Epogen biosimilar launches. Also, concerns swirl around the impending impact of generics on Allergan's blockbuster Restasis, Biogen investors await news on Alzheimer's programs and M&A, and Novartis will face scrutiny of recent launches.

Sales & Earnings Companies

What Does 2019 Hold For Biopharma?

Industry executives, consultants and analysts speculate on what they believe the big themes, trends and events will be this year.

C-Suite Speaks Business Strategies

Scrip Asks...What Does 2019 Hold For Biopharma? Part 3: Pricing, Reimbursement And Market Access

How much therapies should cost and how they should be reimbursed are questions that are expected to dominate in 2019, according to industry experts and participants interviewed by Scrip on their expectations for the coming year. This is the focus for the final installment of our three-part Scrip Asks series.

Pricing Debate Pricing Strategies

Scrip Asks… What Does 2019 Hold For Biopharma? Part 2: Business Trends

What do biopharma leaders and experts expect for the coming year? Following on from therapeutic area insights in part 1, our interviewees consider the outlook for business trends, from M&A and financing to digital strategy, AI and organizational management.

Business Strategies Financing
See All
Advertisement
UsernamePublicRestriction

Register